If until recently the KRAS mutation was considered un-targetable, the recent introduction of specific inhibitors of the KRAS G12C mutation in patients with advanced lung cancer has been followed with great enthusiasm, considering that about half of patients with mCRC has a KRAS mutation. The gene discussed is KRAS; the disease is lung carcinoma.